We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS SEEKS EXCLUSIVITY ON DRUG FACING GENERIC COMPETITION
BMS SEEKS EXCLUSIVITY ON DRUG FACING GENERIC COMPETITION
April 2, 2004
Bristol-Myers Squibb (BMS) has filed data with the FDA from two clinical studies involving the pediatric use of its profitable cancer drug Paraplatin (carboplatin). The move was aimed at avoiding generic competition by an additional six months, the company said last week.